LUO Bin, QUE Zu-jun, ZHU Li-hua, et al
Current Immunology.
2017, 37(1):
25-31.
The aim of this study is to explore the correlation of clinical stages and the immune status with the level of myeloid-derived suppressor cells (MDSC) in the peripheral blood in patients with non-small cell lung cancer (NSCLC). Blood samples were collected from peripheral vein of 116 patients with NSCLC and 30 healthy volunteers. The ratios of MDSCs and Tregs in PBMC were detected by flow cytometry and the relationships with clinical stages, pathological types as well as the immunity were also researched. The results showed that compared with the healthy group, the rates of G-MDSC and M-MDSC in NSCLC were significant elevated (P<0.05); G-MDSC and pathological types were correlated with clinical stages (n=116, r=0.330, P<0.001; n=116, r=0.441, P<0.001). There was no correlation between the clinical stages and M-MDSC or Tregs (n=116, r=0.053, P=0.558; n=116, r=0.173, P=0.052). The G-MDSC correlated highly with Tregs (n=116, r=0.343, P<0.001), and so with the pathological types (r=0.333, P<0.001). The M-MDSC had no correlation with Tregs (r=0.333, P<0.001) or pathological types (r=-0.143, P=0.109).The level of MDSC in the peripheral blood of NSCLC patients was increased. Furthermore, G-MDSCs were found to have a positive correlation with clinical stages of NSCLC and Tregs. The results indicate that regulating the expression of MDSC may generate a new strategy for preventing occurrence of NSCLC and postoperative recurrence and metastasis [NCT02603003].